http://www.cs.dartmouth.edu/%7Ecbk/deimmunization.php
3
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">

<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">

<head>
<meta http-equiv="content-type" content="text/html;charset=utf-8" />
<title>Chris Bailey-Kellogg | Projects | Deimmunization </title>
<link href="style/main.css" type="text/css" rel="stylesheet" />

</head>

<body>

<div id="page">

<div id="header">
<h2>Chris Bailey-Kellogg</h2>

<div id="title">
 Associate Professor, 
  <a href="http://www.cs.dartmouth.edu/">CS</a>, 
  <a href="http://www.dartmouth.edu/">Dartmouth</a>
  
</div>

<div id="nav">
  <span><a href="index.php"  >home</a></span>
  <span><a href="lab.php"  >lab</a></span>
  <span><a href="projects.php" class="navhere" >projects</a></span>
  <span><a href="classes.php"  >classes</a></span>
  <span><a href="papers.php"  >papers</a></span>
  <span><a href="news.php"  >news</a></span>
</div>
</div>

<div id="content">

<div id="projimg"><img src="img/proj/blac.png" alt="Deimmunization" /></div>

<p>In collaboration with
	<a href="http://engineering.dartmouth.edu/griswold/">Karl Griswold</a> (engineering, Dartmouth), we are developing and experimentally applying a suite of general
methods integrating computation and experiment in order to produce
immunotolerant variants of therapeutic proteins, in which
immunogenicity is reduced while therapeutic activity is maintained.
The majority of therapeutic proteins elicit an anti-biotherapeutic
immune response (aBIR) in human patients, driving the
search for strategies to detect, assess, and ameliorate potentially
deleterious immune responses.
Our approach promises not only to improve the state of the art in
humanization of antibodies, but also to open new doors to humanization
of enzymes.</p>

<p>In our DP<sup>2</sup> (Dynamic Programming for Deimmunizing Proteins)
		approach, we
establish as our primary optimization objective reduction of
immunogenicity, according to predicted T-cell epitopes within the
sequence.  In order to also address the complementary/competing concern of
maintaining stability and activity, we identify for each residue position those
mutations that are deemed acceptable according to sequence and/or
structure-based analyses.  A dynamic programming approach then finds
globally optimal and near-optimal sets of these acceptable mutations
that minimize the occurrence of predicted epitopes.</p>

<p>In our IP<sup>2</sup> (Integer Programming for Immunogenic Proteins)
		 approach, we extend the objective to account for residue interactions, e.g., based on pairwise covariation analysis from a set of homologs.  Thus we seek to delete immunogenic
  T-cell epitopes, as evaluated by a 9-mer potential, while
  simultaneously maintaining important residues and residue
  interactions, as evaluated by one- and two-body potentials.
An integer programming approach finds sets of mutations optimizing a specified trade-off between these objectives.</p>

<h4>Software</h4>

<ul>
  <li><a href="http://www.cs.dartmouth.edu/~cbk/deimm/dpdp/">DP<sup>2</sup> demo</a></li>
  <li><a href="http://www.cs.dartmouth.edu/~cbk/deimm/ipip/">IP<sup>2</sup> demo</a></li>
  <li><a href="http://www.cs.dartmouth.edu/~cbk/pepfr/">PEPFR</a> contains an improved version of IP<sup>2</sup>, mapping the whole Pareto frontier of epitope score vs. sequence potential (1- and 2-body).</li>
  <li><a name="methods"></a>We have available upon request a set of pre- and post-processing scripts for setting up the potentials, evaluating and plotting epitopes, etc.</li>
</ul>

<h4>Papers</h4>
<ul>
    <li>D.C. Osipovitch, A.S. Parker, C.D. Makokha, J. Desrosiers, W.C. Kett, L. Moise, C. Bailey-Kellogg, and K.E. Griswold, "Design and analysis of immune-evading enzymes for ADEPT therapy", <i>Protein Eng. Des. Sel.</i>, 2012, 25:613-624. <a href="papers.php?abs=81">[abstract] </a><a href="http://peds.oxfordjournals.org/content/25/10/613.long">[paper] </a></li>
    <li>A.S. Parker, K.E. Griswold, and C. Bailey-Kellogg, "Structure-guided deimmunization of therapeutic proteins", <i>Proc. RECOMB</i>, 2012, 184-198. <a href="papers.php?abs=74">[abstract] </a><a href="papers/recomb12a.pdf">[preprint] </a></li>
    <li>L. He, A.M. Friedman, and C. Bailey-Kellogg, "A divide-and-conquer approach to determine the Pareto frontier for optimization of protein engineering experiments'", <i>Proteins</i>, 2012, 80:790-806. <a href="papers.php?abs=73">[abstract] </a><a href="http://dx.doi.org/10.1002/prot.23237">[paper] </a></li>
		<li>A.S. Parker, K.E. Griswold, and C. Bailey-Kellogg, "Optimization of therapeutic proteins to delete T-cell epitopes while maintaining beneficial residue interactions", <i>J. Bioinf. Comp. Biol.</i>, 2011, 9:207-229. <a href="papers.php?abs=65">[abstract] </a><a href="http://dx.doi.org/10.1142/S0219720011005471">[paper]</a><br/>
    (Originally presented at <i>Comp. Syst. Bioinf.</i> 2010.)</li>
		<li>A.S. Parker, W. Zheng, K.E. Griswold, and C. Bailey-Kellogg, "Optimization algorithms for functional deimmunization of therapeutic proteins", <i>BMC Bioinf.</i>, 2010, 11:180. <a href="papers.php?abs=57">[abstract] </a><a href="http://www.biomedcentral.com/1471-2105/11/180/abstract">[paper] </a></li>
</ul>

</div>

<div id="footer"></div>

</div>

</body>
</html>
